Search

Your search keyword '"Chermat A"' showing total 12 results
Start Over Author "Chermat A" Journal leukemia
12 results on '"Chermat A"'

1. Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myélodysplasies (GFM) study

Author

Rabian, Florence, Chevret, Sylvie, Gruson, Bérengère, Thépot, Sylvain, Walter-Petrich, Anouk, Braun, Thorsten, Vey, Norbert, Torregrosa-Diaz, José Miguel, Peterlin, Pierre, Toma, Andrea, D’Aveni, Maud, Delaunay, Jacques, Legros, Laurence, Droin, Nathalie, Chermat, Fatiha, Lusina, Daniel, Adès, Lionel, Sapena, Rosa, Solary, Eric, Fenaux, Pierre, and Itzykson, Raphael

Published
2024
Full Text
View/download PDF

2. Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens

Author

Sébert, Marie, Freiman, Lucie, Chaffaut, Cendrine, Guerci, Agnès, Peterlin, Pierre, Thépot, Sylvain, Beyne-Rauzy, Odile, Park, Sophie, Cluzeau, Thomas, Chermat, Fatiha, Fenaux, Pierre, Preudhomme, Claude, Clappier, Emmanuelle, Chevret, Sylvie, Adès, Lionel, Duployez, Nicolas, and Duchmann, Matthieu

Published
2024
Full Text
View/download PDF

3. Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

Author

Kubasch, A. S., Peterlin, P., Cluzeau, T., Götze, K. S., Sockel, K., Teipel, R., Jentzsch, M., Attalah, H., Sebert, M., Chermat, F., Gloaguen, S., Puttrich, M., Cross, M., Schneider, M., Kayser, S., Schipp, D., Giagounidis, A., Tirado-Gonzalez, I., Descot, A., van de Loosdrecht, A., Weigert, A., Metzeler, K. H., Fenaux, P., Medyouf, H., Platzbecker, U., and Ades, L.

Published
2023
Full Text
View/download PDF

4. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML

Author

Mekinian, Arsene, Zhao, Lin Pierre, Chevret, Sylvie, Desseaux, Kristell, Pascal, Laurent, Comont, Thibaut, Maria, Alexandre, Peterlin, Pierre, Terriou, Louis, D’Aveni Piney, Maud, Gourin, Marie-Pierre, Vey, Norbert, Rauzy, Odile Beyne, Grobost, Vincent, Bezanahary, Holy, Dimicoli-Salazar, Sophie, Banos, Anne, Wickenhauser, Stefan, De Renzis, Benoit, Durot, Eric, Natarajan-Amé, Shanti, Voillat, Laurent, Chermat, Fatiha, Lemaire, Karine, Jachiet, Vincent, Himberlin, Chantal, Thépot, Sylvain, Diaz, Jose Miguel Torregrosa, Frenzel, Laurent, Gyan, Emmanuel, Denis, Guillaume, Hirsch, Pierre, Kosmider, Olivier, Ades, Lionel, Fain, Olivier, and Fenaux, Pierre

Published
2022
Full Text
View/download PDF

5. Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO

Author

Kubasch, Anne Sophie, Giagounidis, Aristoteles, Metzgeroth, Georgia, Jonasova, Anna, Herbst, Regina, Diaz, Jose Miguel Torregrosa, De Renzis, Benoit, Götze, Katharina S., Huetter-Kroenke, Marie-Luise, Gourin, Marie-Pierre, Slama, Borhane, Dimicoli-Salazar, Sophie, Cony-Makhoul, Pascale, Laribi, Kamel, Park, Sophie, Jersemann, Katja, Schipp, Dorothea, Metzeler, Klaus H., Tiebel, Oliver, Sockel, Katja, Gloaguen, Silke, Mies, Anna, Chermat, Fatiha, Thiede, Christian, Sapena, Rosa, Schlenk, Richard F., Fenaux, Pierre, Platzbecker, Uwe, and Adès, Lionel

Published
2022
Full Text
View/download PDF

6. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

Author

Kubasch, Anne Sophie, Schulze, Freya, Giagounidis, Aristoteles, Götze, Katharina S., Krönke, Jan, Sockel, Katja, Middeke, Jan Moritz, Chermat, Fatiha, Gloaguen, Silke, Puttrich, Martin, Weigt, Carmen, William, Doreen, Fenaux, Pierre, Schlenk, Richard F., Thiede, Christian, Stasik, Sebastian, Mies, Anna, Adès, Lionel, Oelschlägel, Uta, and Platzbecker, Uwe

Published
2020
Full Text
View/download PDF

7. Clinical impact of genetic alterations including germline DDX41mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens

Author

Sébert, Marie, Freiman, Lucie, Chaffaut, Cendrine, Guerci, Agnès, Peterlin, Pierre, Thépot, Sylvain, Beyne-Rauzy, Odile, Park, Sophie, Cluzeau, Thomas, Chermat, Fatiha, Fenaux, Pierre, Preudhomme, Claude, Clappier, Emmanuelle, Chevret, Sylvie, Adès, Lionel, Duployez, Nicolas, and Duchmann, Matthieu

Published
2024
Full Text
View/download PDF

8. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML

Author

Arsene Mekinian, Lin Pierre Zhao, Sylvie Chevret, Kristell Desseaux, Laurent Pascal, Thibaut Comont, Alexandre Maria, Pierre Peterlin, Louis Terriou, Maud D’Aveni Piney, Marie-Pierre Gourin, Norbert Vey, Odile Beyne Rauzy, Vincent Grobost, Holy Bezanahary, Sophie Dimicoli-Salazar, Anne Banos, Stefan Wickenhauser, Benoit De Renzis, Eric Durot, Shanti Natarajan-Amé, Laurent Voillat, Fatiha Chermat, Karine Lemaire, Vincent Jachiet, Chantal Himberlin, Sylvain Thépot, Jose Miguel Torregrosa Diaz, Laurent Frenzel, Emmanuel Gyan, Guillaume Denis, Pierre Hirsch, Olivier Kosmider, Lionel Ades, Olivier Fain, and Pierre Fenaux

Subjects
Cancer Research, Oncology, Hematology
Published
2022
Full Text
View/download PDF

9. Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO

Author

Anne Sophie Kubasch, Aristoteles Giagounidis, Georgia Metzgeroth, Anna Jonasova, Regina Herbst, Jose Miguel Torregrosa Diaz, Benoit De Renzis, Katharina S. Götze, Marie-Luise Huetter-Kroenke, Marie-Pierre Gourin, Borhane Slama, Sophie Dimicoli-Salazar, Pascale Cony-Makhoul, Kamel Laribi, Sophie Park, Katja Jersemann, Dorothea Schipp, Klaus H. Metzeler, Oliver Tiebel, Katja Sockel, Silke Gloaguen, Anna Mies, Fatiha Chermat, Christian Thiede, Rosa Sapena, Richard F. Schlenk, Pierre Fenaux, Uwe Platzbecker, and Lionel Adès

Subjects
Hemoglobins, Cancer Research, Treatment Outcome, Thrombopoietin, Oncology, Myelodysplastic Syndromes, Neoplasms, Recombinant Fusion Proteins, Humans, Receptors, Fc, Hematology, Biomarkers
Abstract

The EUROPE phase 2 trial investigated the predictive value of biomarkers on the clinical efficacy of single agent romiplostim (ROM) treatment in patients with lower-risk myelodysplastic neoplasms (LR-MDS) and thrombocytopenia within the ‘European Myelodysplastic Neoplasms Cooperative Group‘ (EMSCO) network. A total of 77 patients with LR-MDS and a median platelet count of 25/nl were included, all patients received ROM at a starting dose of 750 μg by SC injection weekly. Thirty-two patients (42%) achieved a hematologic improvement of platelets (HI-P) with a median duration of 340 days. Neutrophil (HI-N) and erythroid (HI-E) responses were observed in three (4%) and seven (9%) patients, respectively. We could not confirm previous reports that HI-P correlated with baseline endogenous thrombopoietin levels and platelet transfusion history, but SRSF2 mutation status and hemoglobin levels at baseline were significantly linked to HI-P. Sequential analysis of variant allelic frequency of mutations like SRSF2 did not reveal an impact of ROM on clonal evolution in both responders and non-responders. In summary, our study confirms the safety and efficacy of ROM in LR-MDS patients and may allow to better define subgroups of patients with a high likelihood of response.

Published
2022
Full Text
View/download PDF

11. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

Author

Kubasch, Anne Sophie, primary, Schulze, Freya, additional, Giagounidis, Aristoteles, additional, Götze, Katharina S., additional, Krönke, Jan, additional, Sockel, Katja, additional, Middeke, Jan Moritz, additional, Chermat, Fatiha, additional, Gloaguen, Silke, additional, Puttrich, Martin, additional, Weigt, Carmen, additional, William, Doreen, additional, Fenaux, Pierre, additional, Schlenk, Richard F., additional, Thiede, Christian, additional, Stasik, Sebastian, additional, Mies, Anna, additional, Adès, Lionel, additional, Oelschlägel, Uta, additional, and Platzbecker, Uwe, additional

Published
2019
Full Text
View/download PDF

12. Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases

Author

Ghandi Damaj, Odile Beyne-Rauzy, Borhane Slama, Stéphane Cheze, E. Berger, Francois Dreyfus, A. Kolb, L. Ades, F Bauduer, S Ayari, Raphael Itzykson, Norbert Vey, Felipe Suarez, Laurence Legros, Xavier Thomas, Martine Gardembas, Fatiha Chermat, M.C. Chaury, D. Vassilief, Pierre Fenaux, Agnès Guerci, and Aspasia Stamatoullas

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Neutropenia, Neutrophils, Anemia, Tretinoin, Lower risk, Gastroenterology, Leukocyte Count, Young Adult, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Erythropoietin, Aged, Aged, 80 and over, Cytopenia, Hematology, Platelet Count, business.industry, Myelodysplastic syndromes, Middle Aged, medicine.disease, Thrombocytopenia, Recombinant Proteins, Treatment Outcome, Oncology, Myelodysplastic Syndromes, Immunology, Drug Therapy, Combination, Female, business, medicine.drug
Abstract

Erythropoiesis-stimulating agents (ESAs) remain the first-line treatment of anemia in lower risk myelodysplastic syndromes (MDS) without 5q deletion. A preliminary report suggested that adding all-trans retinoic acid (ATRA) to ESAs may improve their erythroid response, particularly in patients with high endogenous erythropoietin (EPO) level, and may improve other cytopenias. We conducted a prospective multicenter study of EPO-beta and ATRA in anemic MDS patients with marrow blasts10% and either previous ESA failure or relapse, endogenous EPO500 U/l or other cytopenia(s) (absolute neutrophilic count1.0 G/l or platelets50 G/l). A total of 59 patients were evaluable after 12 weeks of treatment. The erythroid response rates according to IWG 2000 and 2006 criteria, respectively, were as follows: overall: 49 and 36%; patients with previous ESA failure (n=28): 43 and 32%; patients with endogenous EPO500 U/l (n=18): 11 and 19%; patients transfused2 red blood cells units/month (n=28) 43 and 39%. Only one neutrophil, but no platelet response, and no major side effect were observed. EPO-beta-ATRA combination appears a possible therapeutic option in anemia of MDS having failed an ESA alone, but not in patients with high endogenous EPO level, and does not improve neutropenia and thrombocytopenia.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results